Bioscibex Receives CHF 150,000 from Venture Kick

EPFL spin-off Bioscibex, a biotechnology start-up specialising in bioproduction equipment, has secured CHF 150,000 in funding from Venture Kick. This fundraising will accelerate the market launch of Swingo, its first single-use bioreactor, designed to simplify and automate cell culture and thus make biological therapies more accessible.

Biologics have transformed the treatment of cancer, autoimmune diseases and many other serious conditions. However, their high cost—due to complex and expensive manufacturing processes—remains a major barrier to patient access. Current bioreactor systems rely on lengthy, multi-step and highly manual processes, which increase costs, slow down development and increase the risk of contamination.

With Swingo, Bioscibex offers a radically simplified alternative: this single-use bioreactor reduces the traditional seven-step cell culture process to just two steps. The result: less handling, less risk of cross-contamination and significantly reduced operating costs. With a scalable culture volume of 30 mL to 30 L, Swingo covers a wide range of applications, from R&D to large-scale production. Unlike conventional solutions, it combines simplicity and automation on a single platform, offering biopharmaceutical companies a faster, more flexible and efficient path to bioproduction.

Bioscibex operates in a global market valued at £6 billion for orbital shaker incubators and bioreactors, dominated by players such as Cytiva, Sartorius, Thermo Fisher and Kuhner Shaker. Within this market, Swingo is targeting a segment estimated at around USD 1 billion. Its potential customers include biopharmaceutical companies, contract manufacturing organisations (CMOs) and biotechnology companies. Venture Kick’s contribution will help secure initial sales to demonstration customers.

Founded in 2024, Bioscibex is led by Chloé Albietz (CEO) and Francois Carruzzo (CTO), two seasoned experts in biopharmaceutical engineering. The company has already raised CHF 1 million and is attracting early interest from major pharmaceutical manufacturers. With the support of Venture Kick, it is preparing for its commercial launch in the second quarter of 2026, with the ambition of setting a new standard in bioreactor technology.

‘Bioscibex is proud to have received the support of Venture Kick, a symbol of quality and credibility in the Swiss start-up ecosystem and beyond,’ said Chloé Albietz. ‘This initial funding also comes with strategic advice and contacts with investors and major players in the sector.’

➡️ Source: Venture Kick Press Release | 📸 CEO Chloé Albietz et CTO François Carruzzo, ©Bioscibex